NanOlogy
  • Home
  • About
  • Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
    • Partnering Opportunities
  • News & Publications
    • Recent News Highlights
    • Press Release Archives
    • NanOlogy In the News
    • Presentations & Publications Archive
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
Post placeholder image
August 9, 2017 in Publications

Cancer Chemotherapy & Pharmacology: Phase I study of intraperitoneal nanoparticulate paclitaxel (nanotax®) in patients with peritoneal malignancies

NanOlogy 0 Like Post Comments Off on Cancer Chemotherapy & Pharmacology: Phase I study of intraperitoneal nanoparticulate paclitaxel (nanotax®) in patients with peritoneal malignancies

Phase I study of intraperitoneal nanoparticulate paclitaxel (nanotax®) in patients with peritoneal malignancies  

Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal